• Explore /
  • Poster
  • / Phase II study of trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC).

Phase II study of trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC).

Abstract Poster

Authors

Sarbajit Mukherjee

Sarbajit Mukherjee

Roswell Park Comprehensive Cancer Center, Buffalo, NY

Sarbajit Mukherjee , Hussein Assi , Christos Fountzilas , Kristopher Attwood , Patrick McKay Boland , Renuka V. Iyer , Daniel V.T. Catenacci , Hassan Hatoum

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04097028

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS464)

Abstract #

TPS464

Poster Bd #

L8

Abstract Disclosures

Similar Posters

First Author: Karyn A. Goodman

First Author: Antoine Adenis

First Author: Richard Francis Dunne

First Author: Ning Li